Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 09/30/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 164.90K | 155.00K | 109.20K | 109.20K | 90.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 164.90K | 155.00K | 109.20K | 109.20K | 90.40K |
| Cost of Revenue | 80.30K | 51.90K | 41.10K | 41.10K | 60.80K |
| Gross Profit | 84.60K | 103.10K | 68.20K | 68.20K | 29.60K |
| SG&A Expenses | 266.90K | 501.80K | 304.70K | 304.70K | 370.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 347.20K | 553.70K | 345.70K | 345.70K | 431.50K |
| Operating Income | -182.30K | -398.70K | -236.50K | -236.50K | -341.10K |
| Income Before Tax | -279.20K | -592.60K | 577.20K | 577.20K | -645.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -279.20K | -592.60K | 577.20K | 577.20K | -645.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -279.20K | -592.60K | 577.20K | 577.20K | -645.80K |
| EBIT | -182.30K | -398.70K | -236.50K | -236.50K | -341.10K |
| EBITDA | -176.90K | -393.20K | -230.60K | -230.60K | -335.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 7.60B | 7.60B | 7.59B | 7.59B | 7.47B |
| Average Diluted Shares Outstanding | 7.60B | 7.60B | 15.60B | 15.60B | 7.47B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |